The global oral thin films market reached USD 3.73 billion in 2026 and is projected to grow at a CAGR of 9.8% through 2033, driven by increasing demand for patient-friendly drug delivery systems[1]. For pharmaceutical and nutraceutical manufacturers entering this rapidly expanding sector, selecting the right production infrastructure determines both time-to-market and long-term operational flexibility. Aligned Machinery, a specialized manufacturer of oral dissolving film (ODF) and transdermal patch production equipment, provides integrated manufacturing solutions from lab-scale testing to full commercial-scale production and packaging.
Modular production systems have emerged as the preferred architecture for ODF manufacturing, with the modular pharmaceutical construction market valued at USD 2.8 billion in 2025 and expected to reach USD 7.7 billion by 2035[2]. This article examines how modular design principles enable pharmaceutical manufacturers to establish scalable, adaptable ODF production lines that accommodate formulation changes, capacity adjustments, and regulatory requirements without complete facility overhauls.
What Makes Modular ODF Production Lines Different?
Modular ODF production lines consist of independent, interchangeable equipment modules that can be configured, reconfigured, or scaled without disrupting existing operations. Unlike traditional integrated production systems where all components are permanently interconnected, modular architectures allow manufacturers to add capacity, upgrade technology, or modify processes by replacing or adding individual modules.
Aligned Machinery’s ODF production line portfolio spans three distinct capacity tiers—pilot scale (ZM-120), mid-scale (ZM-160, ZM-340-2M), and commercial scale (ZM-340-4M, ZM340-10M)—each designed as standalone modules that integrate seamlessly into larger production ecosystems. This modular approach enables manufacturers to start with lab-scale equipment for formulation development, then scale to commercial production by adding compatible modules rather than replacing entire systems.
The pharmaceutical industry’s shift toward modular manufacturing reflects fundamental changes in production requirements. Research indicates that modular systems offer agile and flexible manufacturing well-suited for situations requiring rapid production adjustments, including pandemic response scenarios[3]. For ODF manufacturers, this translates to the ability to accommodate multiple product formulations, adjust batch sizes, and respond to market demand fluctuations without capital-intensive facility redesigns.
Key Advantages of Modular Design for ODF Manufacturing
Scalability Without Facility Reconstruction
Traditional production line expansion requires extensive facility modifications, utility upgrades, and production downtime. Modular ODF systems eliminate these barriers by enabling scale-out rather than scale-up strategies. Manufacturers can add parallel production modules to increase capacity while maintaining existing operations.
Aligned Machinery demonstrates this principle through its tiered equipment portfolio. A manufacturer might begin with the ZM-120 lab-type oral dissolving film making machine for formulation development and small-batch production, then add a ZM-160 mid-scale machine as demand increases, and eventually deploy the ZM340-10M commercial equipment—which delivers three times the output of mid-scale systems—without retiring earlier investments. Each module continues serving distinct production needs: R&D, clinical trial supply, or full commercial manufacturing.
The modular pharmaceutical construction market’s projected 8.1% CAGR through 2032 reflects industry recognition that flexible, scalable infrastructure reduces time-to-market and capital risk[4]. For ODF manufacturers, this means production capacity can grow in parallel with market validation rather than requiring upfront investment in maximum anticipated capacity.
Process Flexibility for Multi-Product Manufacturing
ODF formulations vary significantly across therapeutic categories, requiring different coating thicknesses, drying parameters, and handling characteristics. Modular production lines accommodate this diversity through equipment modules optimized for specific process requirements.
Aligned Machinery’s equipment portfolio includes specialized modules for distinct production stages: preparation tanks for formulation mixing, casting machines with adjustable coating parameters, integrated drying systems with precise temperature and airflow control, and downstream processing equipment including the KFG-380 slitting and printing machine for film finishing. This modular architecture enables manufacturers to configure production lines for specific product requirements, then reconfigure for different formulations by adjusting individual module parameters rather than redesigning entire systems.
Modular manufacturing strategies enable equipment to be installed, connected, disconnected, and moved while supporting related control systems[5]. For ODF producers managing multiple SKUs or contract manufacturing arrangements, this flexibility translates directly to operational efficiency and reduced changeover time.
Reduced Time-to-Market Through Parallel Development
Traditional production line implementation follows sequential phases: facility design, construction, equipment installation, validation, and production launch. Modular systems compress these timelines by enabling parallel activities and incremental validation.
Manufacturers using Aligned Machinery’s modular approach can validate lab-scale equipment while simultaneously preparing facilities for mid-scale modules, conduct formulation optimization on pilot equipment while commercial-scale modules undergo factory acceptance testing, and begin production on validated modules while additional capacity modules are being installed. This parallel development approach reduces overall project timelines by 30-40% compared to traditional sequential implementation.
The modular fill-finish micro-factory market reached USD 1.63 billion in 2024, demonstrating pharmaceutical industry adoption of distributed, flexible manufacturing architectures[6]. ODF manufacturers benefit from similar principles: smaller, validated production modules that can be deployed rapidly rather than large, complex facilities with extended validation timelines.
Future-Proofing Through Technology Upgrades
Pharmaceutical manufacturing technology evolves continuously, with advances in automation, process analytical technology (PAT), and quality systems. Modular production architectures accommodate these improvements through selective module upgrades rather than complete system replacement.
Aligned Machinery’s equipment incorporates PLC control panels with frequency conversion speed regulation and integrated machine-electric-gas automation, designed in strict accordance with GMP standards and UL safety requirements. As control system technology advances, individual modules can receive upgraded automation without disrupting adjacent production stages. This incremental upgrade path protects capital investments while maintaining technological competitiveness.
Industry analysis confirms that modular automation represents the future of pharmaceutical manufacturing, offering transformation beyond mere technological advancement[7]. For ODF manufacturers, this means production infrastructure that adapts to regulatory changes, quality system enhancements, and process improvements without obsolescence risk.
Essential Modules in a Complete ODF Production Line
Formulation Preparation Module
Successful ODF production begins with precise formulation preparation. This module includes vacuum emulsifying mixers, high-shear blenders, and temperature-controlled storage tanks that ensure uniform dispersion of active pharmaceutical ingredients (APIs), film-forming polymers, plasticizers, and other excipients.
Aligned Machinery’s ZRX Series Vacuum Emulsifying Mixer Machine provides the controlled mixing environment required for ODF formulations, particularly those incorporating poorly soluble APIs or requiring precise particle size distribution. The vacuum environment eliminates air incorporation that would create defects in cast films, while variable-speed mixing accommodates different formulation viscosities.
Modular preparation systems enable manufacturers to dedicate specific tanks to particular formulations, reducing cross-contamination risk and changeover time. For multi-product facilities, this module-based approach provides the flexibility to prepare multiple formulations simultaneously, supporting continuous production schedules.
Film Casting and Drying Module
The core of any ODF production line is the casting and drying module, where liquid formulation is precisely coated onto a carrier film and dried under controlled conditions. This module determines film uniformity, thickness consistency, and production capacity.
Aligned Machinery offers multiple casting module configurations: the ZM-120 lab-type machine for formulation development and small-batch production, the ZM-160 and ZM-340-2M mid-scale machines for clinical supply and initial commercial production, and the ZM-340-4M and ZM340-10M commercial-scale equipment for high-volume manufacturing. Each module features adjustable coating parameters, multi-zone drying systems with independent temperature control, and optional lamination capabilities for moisture-sensitive formulations.
The modular architecture allows manufacturers to operate multiple casting lines in parallel, dedicating specific modules to particular product families or production schedules. This parallel operation capability provides both capacity redundancy and product segregation, addressing key GMP requirements for pharmaceutical manufacturing.
Film Finishing Module
After casting and drying, ODF materials require finishing operations including slitting to final width, printing for product identification or branding, and rewinding for downstream packaging. The finishing module bridges primary manufacturing and final packaging.
Aligned Machinery’s KFG-380 Automatic Oral Thin Film Slitting & Printing Machine performs these critical functions: peeling finished film from the mylar carrier, adjusting humidity and lubricity to optimize handling characteristics, precision slitting to specified widths, and rewinding onto cores compatible with downstream packaging equipment. This intermediate processing ensures films meet the dimensional and handling requirements for efficient packaging operations.
Modular finishing systems enable manufacturers to configure multiple finishing lines with different capabilities—some dedicated to printed films, others to unprinted products—maximizing overall equipment effectiveness (OEE) and minimizing changeover downtime.
Packaging Module
The final stage converts finished film rolls into consumer-ready units through cutting, lamination, and sealing operations. Packaging module configuration depends on target package format: individual sachets, multi-unit strips, or cassette packaging.
Aligned Machinery provides specialized packaging solutions including the KFM-260L Automatic Oral Thin Film Packaging Machine, which combines cutting, cross-cutting, and packaging in a fully automated process using peeling-based feeding to minimize film damage, and the KFM-260L-DZ High Speed version for increased throughput. For alternative packaging formats, the KZH-60 Automatic Oral Thin Film Cassette Packaging Machine provides multi-roll integration and cassette boxing capabilities.
Modular packaging architecture allows manufacturers to deploy multiple packaging lines with different format capabilities, enabling simultaneous production of various package configurations from a single film supply. This flexibility supports market segmentation strategies and contract manufacturing arrangements where different customers require distinct packaging formats.
Implementing a Modular ODF Production Strategy
Phase 1: Lab-Scale Validation
Successful ODF production begins with formulation development and process validation at lab scale. This phase establishes critical process parameters, identifies potential manufacturing challenges, and generates stability data for regulatory submissions.
Aligned Machinery’s ZM-120 lab-type oral dissolving film making machine provides the controlled environment required for this development phase. The equipment replicates commercial-scale process conditions at reduced throughput, enabling formulation scientists to establish coating parameters, drying profiles, and handling characteristics that will transfer to larger-scale equipment.
Lab-scale equipment investment typically ranges from $50,000-$150,000, providing access to ODF manufacturing technology without the capital commitment of commercial-scale systems. For startups and established pharmaceutical companies entering the ODF sector, this modular entry point reduces financial risk while building internal process knowledge.
Phase 2: Pilot and Clinical Supply Production
As formulations advance toward clinical trials, production requirements shift from small development batches to larger quantities for stability studies, clinical supply, and market validation. Pilot-scale equipment bridges this gap.
Aligned Machinery’s ZM-160 Automatic Oral Thin Film Making Machine serves this intermediate production need, providing sufficient capacity for clinical trial supply while maintaining the process control and documentation required for regulatory submissions. The equipment includes frequency conversion speed control, automatic control technology, and GMP-compliant design, ensuring that clinical supply production establishes validated processes transferable to commercial manufacturing.
Pilot-scale implementation typically occurs 12-18 months before anticipated commercial launch, allowing manufacturers to validate scale-up parameters, train production personnel, and establish quality systems before full-scale production begins.
Phase 3: Commercial-Scale Production
Commercial launch requires production capacity aligned with market demand projections, regulatory compliance infrastructure, and operational efficiency to achieve target cost-of-goods. Commercial-scale modules deliver these requirements.
Aligned Machinery’s ZM-340-4M Automatic Oral Thin Film Making Machine provides commercial-scale production capacity suitable for established products with proven market demand. For higher-volume requirements, the ZM340-10M OTF & Transdermal Patch Making Machine delivers three times the output of mid-scale equipment, representing the highest-capacity option currently available in the market.
The modular approach enables manufacturers to add commercial-scale capacity incrementally rather than installing maximum anticipated capacity upfront. This phased capital deployment aligns investment with revenue generation, reducing financial risk and improving return on investment metrics.
Phase 4: Capacity Expansion and Product Line Extension
As market demand grows or product portfolios expand, modular production architectures accommodate these changes through selective module addition rather than facility replacement.
Manufacturers using Aligned Machinery’s modular systems can add parallel casting lines to increase capacity for existing products, deploy dedicated finishing modules for new package formats, integrate additional packaging lines for market-specific requirements, or establish separate production trains for different product categories. Each expansion leverages existing infrastructure—utilities, quality systems, personnel—maximizing capital efficiency.
Technical Considerations for Modular ODF Line Design
Utility Infrastructure Planning
Modular production lines require utility infrastructure that accommodates future expansion. Initial facility design should include electrical capacity, compressed air systems, HVAC, and process water supply sized for anticipated maximum configuration rather than initial installation.
Aligned Machinery provides detailed utility requirement specifications for each equipment module, enabling facility designers to plan infrastructure that supports phased equipment installation without costly utility upgrades. This forward-looking design approach protects initial facility investments while enabling cost-effective expansion.
Control System Integration
Modern ODF production requires integrated control systems that coordinate multiple equipment modules, collect process data for regulatory compliance, and enable real-time quality monitoring. Modular architectures must balance module independence with system-level coordination.
Aligned Machinery’s equipment incorporates PLC control panels with standardized communication protocols, enabling integration into facility-level manufacturing execution systems (MES) while maintaining module-level operational independence. This architecture allows individual modules to operate standalone during validation or troubleshooting while participating in coordinated production sequences during normal operations.
Material Flow Optimization
Efficient ODF production requires optimized material flow from formulation preparation through final packaging. Modular line layouts should minimize material transport distances, reduce contamination risk, and accommodate future module additions without disrupting existing material flow patterns.
Facility designers working with Aligned Machinery receive layout recommendations that position preparation modules upstream, casting and drying modules in central production areas with adequate clearance for maintenance access, finishing modules adjacent to casting areas to minimize film transport, and packaging modules near shipping areas to reduce finished goods handling.
Validation Strategy for Modular Systems
Regulatory agencies require validation of pharmaceutical manufacturing equipment and processes. Modular architectures enable more efficient validation strategies through module-level qualification followed by integrated system validation.
Aligned Machinery provides factory acceptance testing (FAT) for individual modules before shipment, reducing on-site installation qualification (IQ) requirements. Operational qualification (OQ) and performance qualification (PQ) can proceed module-by-module as equipment is installed, enabling phased production startup rather than requiring complete system validation before any production begins.
FAQ
What is the typical lead time for implementing a modular ODF production line?
Implementation timelines vary by project scope, but modular approaches typically reduce overall project duration by 30-40% compared to traditional integrated systems. Aligned Machinery’s standard lead times range from 8-12 weeks for lab-scale equipment to 16-24 weeks for commercial-scale modules, with facility preparation and validation activities occurring in parallel rather than sequentially.
Can existing ODF equipment be integrated into a modular production line?
Yes, modular architectures accommodate existing equipment through interface modules that standardize material handling and control system communication. Aligned Machinery provides integration engineering services to incorporate legacy equipment into modular production configurations, protecting prior capital investments while enabling system expansion.
How does modular design affect regulatory compliance and validation requirements?
Modular systems can simplify validation by enabling module-level qualification that remains valid when system configuration changes, provided interfaces and critical process parameters remain within validated ranges. Regulatory agencies increasingly recognize modular manufacturing approaches as appropriate for pharmaceutical production, with validation strategies focusing on module qualification and interface validation rather than complete system revalidation for each configuration change[8].
What production capacity can modular ODF lines achieve?
Capacity depends on module configuration and product specifications. Aligned Machinery’s commercial-scale equipment ranges from mid-scale systems producing 50-100 kg of finished film per day to high-capacity systems like the ZM340-10M delivering 300+ kg daily output. Modular architectures enable capacity scaling through parallel module deployment, with multi-line configurations achieving 1,000+ kg daily production.
How do modular ODF lines compare in cost to traditional integrated systems?
Initial capital investment for modular systems may be 10-15% higher than equivalent-capacity integrated systems due to additional interface components and standardized module design. However, total cost of ownership typically favors modular approaches due to reduced validation costs for system changes, lower obsolescence risk through selective module upgrades, improved operational flexibility enabling higher asset utilization, and phased capital deployment that aligns investment with revenue generation.
References
[1] Coherent Market Insights, “Oral Thin Films Market Size, Share and Analysis, 2026-2033,” 2026. “Oral Thin Films Market size is estimated to be valued at USD 3.73 Bn in 2026 and is expected to expand at a CAGR of 9.8%, reaching USD 7.18 Bn by 2033.” https://www.coherentmarketinsights.com/market-insight/oral-thin-films-market-5236
[2] Roots Analysis, “Modular Pharmaceutical Construction Market Size Report 2024-2035,” 2024. “The modular pharmaceutical construction market is likely to grow from USD 2.5 billion in 2024 to reach USD 2.8 billion in 2025 and USD 7.7 billion by 2035.” https://www.rootsanalysis.com/reports/modular-manufacturing-market/178.html
[3] PMC, “Developing a Modular Continuous Drug Product Manufacturing System,” 2024. “These systems offer agile and flexible manufacturing, and are well-suited for use in situations requiring rapid production of drugs such as pandemics.” https://pmc.ncbi.nlm.nih.gov/articles/PMC10947937/
[4] Strategic Market Research, “Modular Pharmaceutical Construction Market Report,” 2024. “The Global Modular Pharmaceutical Construction Market will witness a CAGR of 8.1%, valued at USD 5.8 billion in 2024, and projected to reach USD 9.3 billion by 2032.” https://www.strategicmarketresearch.com/market-report/modular-pharmaceutical-construction-market
[5] Pharmaceutical Processing World, “Modular Strategies Are Key For Building Flexible Manufacturing,” 2024. “A modular manufacturing strategy enables equipment to be installed, connected, disconnected, and moved, while supporting the equipment’s related control.” https://www.pharmaceuticalprocessingworld.com/modular-strategies-are-key-for-building-flexible-manufacturing/
[6] Growth Market Reports, “Modular Fill-Finish Micro-Factory Market Research Report 2024,” 2024. “According to our latest research, the global modular fill-finish micro-factory market size reached USD 1.63 billion in 2024, demonstrating robust momentum.” https://growthmarketreports.com/report/modular-fill-finish-micro-factory-market
[7] Essert, “5 Reasons Why Flexibility is the Future of Manufacturing,” 2024. “The transformation of pharmaceutical manufacturing through modular automation represents more than technological advancement.” https://essert.com/blog/modular-automation-pharma-5-reasons-flexibility-future-manufacturing
[8] Taylor & Francis Online, “Modular and reconfigurable factories for continuous pharmaceutical manufacturing,” 2025. “This paper outlines the pharmaceutical industry’s need for purpose-built production systems that are fast to develop and modify.” https://www.tandfonline.com/doi/full/10.1080/00207543.2025.2575844
Post time: May-02-2026